Fresenius buys Renal Care for $4bn

The deal has industrial logic, beefing up the German group s presence in US dialysis. But at 17 times operating profit, it won't come cheap. The alldebt financing may help make the numbers work. But it will leave Fresenius very highly leveraged. The deal has industrial logic,beefing up the German group s presence in US dialysis. But at 16 times operating profits, it won't come cheap. The alldebt financing may help make the numbers work. But it will leave Fresenius very highly leveraged.